Non-HDL Cholesterol: what is a good level?
Commonly flagged above 130 mg/dL, with 160 and above treated as high. It is calculated on every standard lipid panel at no extra cost, and is still frequently ignored in favour of LDL-C.
This is the range used by the atherogenic dial in the Longevity Score calculator. It is deliberately tighter than the range printed on a standard lab report — the reasoning is below.
Nothing you type here is sent anywhere, stored, or logged. It never leaves this page.
A result anywhere in the pale band is reported as normal and generates no comment. The brighter band is where risk is lowest. The distance between them is the part a standard report does not tell you.
What Non-HDL Cholesterol actually measures
Total cholesterol minus HDL cholesterol. That subtraction leaves the cholesterol carried by every atherogenic particle — LDL, VLDL, IDL and Lp(a) — rather than LDL alone.
It requires no additional test and no assumptions. LDL-C on most panels is estimated using the Friedewald equation, which becomes unreliable when triglycerides are high; non-HDL avoids that failure mode entirely.
Why it matters
It is the best ApoB proxy available from a standard lipid panel, and ApoB is the better predictor of cardiovascular events. Where ApoB is unavailable or not reimbursed, non-HDL carries most of the same information for free.
It is particularly informative in people with high triglycerides or metabolic syndrome, where LDL-C can look reassuring while total atherogenic particle burden is high.
Unlike LDL-C, it does not require fasting. A non-fasting sample gives a usable non-HDL, which removes a real barrier to testing.
Why it's on the dashboard
Non-HDL cholesterol made the panel because it is the best atherogenic-particle proxy available from a standard panel at no extra cost, and because it survives the one common failure mode — high triglycerides — that breaks calculated LDL-C. The population-risk case: Brunner et al.'s Multinational Cardiovascular Risk Consortium analysis (The Lancet, 2019), pooling data across cohorts, found non-HDL cholesterol of 220 mg/dL or above carried nearly double the cardiovascular disease risk (HR ~1.9) of levels under 145 mg/dL, after adjusting for age, sex and standard risk factors. The 'why decades matter' case, which is exactly the cumulative-exposure argument this dial's threshold is built on: Ference et al.'s Mendelian randomization analysis (JACC, 2016) found each 1 mmol/L of genetically lower LDL cholesterol — the dominant component of non-HDL in most people — maintained from birth cut coronary heart disease risk by roughly 55%, about double the ~20-25% reduction from the same drop achieved later in life with a statin. Lower sooner is worth more than lower later, which is the entire logic behind scoring this strictly rather than waiting for a 'high' flag. See the Atherogenic dial for the broader context.
Why this range is stricter than your lab's
The 130 mg/dL threshold is a treatment-decision point, set roughly 30 mg/dL above the corresponding LDL-C target. It marks where intervention becomes conventional in a high-risk population.
Atherosclerosis is cumulative exposure, so the quantity that matters is the area under the curve across decades. A level that is acceptable at 45 represents a great deal of accumulated particle-years by 70.
The optimised target of under 100 mg/dL reflects where lifetime exposure stays low. It corresponds approximately to an ApoB under 80 mg/dL.
This distinction applies across the whole panel, not just this marker — see optimal versus standard lab ranges for the general case.
What moves Non-HDL Cholesterol
Educational information, not a treatment plan. Discuss changes to medication or supplementation with a clinician who knows your history.
How fast it responds
Six to twelve weeks for dietary change; faster on medication. A steering metric worth retesting after a genuine change rather than monthly. See response times across all markers for how this compares.
What can distort the result
- Requires only total cholesterol and HDL, both of which are on every standard panel — if your report does not state it, it can be calculated from numbers you already have.
- Non-fasting samples are acceptable, unlike calculated LDL-C.
- Acute illness, recent infection and pregnancy all shift lipids; wait several weeks after any of them.
- Where ApoB is available, prefer it. Non-HDL is an excellent proxy, not a replacement — the two occasionally disagree, and ApoB is right when they do.
Frequently asked questions
What is a good Non-HDL Cholesterol level?
The longevity-optimised target used in this calculator is < 100 mg/dL. Commonly flagged above 130 mg/dL, with 160 and above treated as high. It is calculated on every standard lipid panel at no extra cost, and is still frequently ignored in favour of LDL-C.
Why is this target stricter than the range on my lab report?
The 130 mg/dL threshold is a treatment-decision point, set roughly 30 mg/dL above the corresponding LDL-C target. It marks where intervention becomes conventional in a high-risk population.
How fast does Non-HDL Cholesterol respond to change?
Six to twelve weeks for dietary change; faster on medication. A steering metric worth retesting after a genuine change rather than monthly.
Related markers
Non-HDL Cholesterol feeds the atherogenic dial, and read it alongside ApoB · Triglycerides.